NASDAQ:PSTIPluristem Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pluristem Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.74 +0.22 (+2.58 %) (As of 08/12/2020 04:00 PM ET) Add Compare Share Today's Range$8.57Now: $8.74▼$9.0150-Day Range$8.05MA: $8.94▼$11.0452-Week Range$2.82Now: $8.74▼$13.29Volume555,289 shsAverage Volume1.19 million shsMarket Capitalization$222.81 millionP/E RatioN/ADividend YieldN/ABeta2.6 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has a collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingPluristem Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.88, Pluristem Therapeutics has a potential upside of 58.8% from its current price of $8.74.Amount of Analyst CoveragePluristem Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesPluristem Therapeutics has received 367 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPluristem Therapeutics has received 261 “underperform” votes. (Add your “underperform” vote.)Community SentimentPluristem Therapeutics has received 58.44% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Pluristem Therapeutics and other stocks. Vote “Outperform” if you believe PSTI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PSTI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPluristem Therapeutics does not currently pay a dividend.Dividend GrowthPluristem Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pluristem Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,763,002.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.90% of the stock of Pluristem Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 7.82% of the stock of Pluristem Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Pluristem Therapeutics are expected to grow in the coming year, from ($1.49) to ($1.12) per share.Price to Book Value per Share RatioPluristem Therapeutics has a P/B Ratio of 6.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.01 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PSTI Previous Symbol CUSIPN/A CIK1158780 Webwww.pluristem.com Phone972-74-710-8600Debt Debt-to-Equity Ratio0.06 Current Ratio2.47 Quick Ratio2.47Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$50,000.00 Price / Sales4,456.18 Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book6.11Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-35,310,000.00 Net MarginsN/A Return on Equity-152.78% Return on Assets-101.67%Miscellaneous Employees172 Outstanding Shares25,493,000Market Cap$222.81 million Next Earnings DateN/A OptionableOptionable $8.74 +0.22 (+2.58 %) (As of 08/12/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PSTI News and Ratings via Email Sign-up to receive the latest news and ratings for PSTI and its competitors with MarketBeat's FREE daily newsletter. Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions How has Pluristem Therapeutics' stock been impacted by Coronavirus (COVID-19)? Pluristem Therapeutics' stock was trading at $2.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PSTI stock has increased by 202.4% and is now trading at $8.74. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Pluristem Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pluristem Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pluristem Therapeutics. How were Pluristem Therapeutics' earnings last quarter? Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.90) by $0.10. View Pluristem Therapeutics' earnings history. When did Pluristem Therapeutics' stock split? How did Pluristem Therapeutics' stock split work? Shares of Pluristem Therapeutics reverse split before market open on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Pluristem Therapeutics stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for PSTI? 4 brokerages have issued 1 year price objectives for Pluristem Therapeutics' stock. Their forecasts range from $12.00 to $16.00. On average, they anticipate Pluristem Therapeutics' share price to reach $13.88 in the next year. This suggests a possible upside of 58.8% from the stock's current price. View analysts' price targets for Pluristem Therapeutics. Has Pluristem Therapeutics been receiving favorable news coverage? Headlines about PSTI stock have trended extremely negative on Thursday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pluristem Therapeutics earned a media sentiment score of -4.1 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news about Pluristem Therapeutics. Are investors shorting Pluristem Therapeutics? Pluristem Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 1,400,000 shares, a decline of 10.8% from the April 30th total of 1,570,000 shares. Based on an average daily trading volume, of 2,260,000 shares, the days-to-cover ratio is presently 0.6 days. View Pluristem Therapeutics' Short Interest. Who are some of Pluristem Therapeutics' key competitors? Some companies that are related to Pluristem Therapeutics include Poseida Therapeutics (PSTX), Cellectis (CLLS), Vericel (VCEL), BioCryst Pharmaceuticals (BCRX), Passage Bio (PASG), Krystal Biotech (KRYS), Autolus Therapeutics (AUTL), Oyster Point Pharma (OYST), Osiris Therapeutics (OSIR), Avrobio (AVRO), Agenus (AGEN), Aerie Pharmaceuticals (AERI), Fusion Pharmaceuticals (FUSN), Proteon Therapeutics (PRTO) and MeiraGTx (MGTX). View all competitors. What other stocks do shareholders of Pluristem Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pluristem Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), NVIDIA (NVDA), Protalix Biotherapeutics (PLX), Pfizer (PFE), SCYNEXIS (SCYX), Micron Technology (MU) and Sangamo Therapeutics (SGMO). Who are Pluristem Therapeutics' key executives? Pluristem Therapeutics' management team includes the following people: Mr. Zami Aberman, Chairman & Co-CEO (Age 65)Mr. Yaky Yanay, Pres, Co-CEO & Director (Age 48)Ms. Chen Franco-Yehuda, CFO, Treasurer & Sec. (Age 35)Mr. Boaz Leshem, VP Operations & Manufacturing (Age 59)Ms. Efrat Kaduri, Director of Bus., Investor and PR What is Pluristem Therapeutics' stock symbol? Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI." Who are Pluristem Therapeutics' major shareholders? Pluristem Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Meitav Dash Investments Ltd. (0.54%), Sumitomo Mitsui Trust Holdings Inc. (0.45%), Shepherd Financial Partners LLC (0.07%), Algert Global LLC (0.06%), Phoenix Holdings Ltd. (0.06%) and Commonwealth Equity Services LLC (0.06%). Company insiders that own Pluristem Therapeutics stock include Clover Wolf Capital - Limited, Moria Kwiat and Yaky Yanay. View institutional ownership trends for Pluristem Therapeutics. Which major investors are selling Pluristem Therapeutics stock? PSTI stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., and Algert Global LLC. View insider buying and selling activity for Pluristem Therapeutics. Which major investors are buying Pluristem Therapeutics stock? PSTI stock was acquired by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd., Shepherd Financial Partners LLC, Phoenix Holdings Ltd., Commonwealth Equity Services LLC, Focused Wealth Management Inc, UBS Group AG, and Evolution Wealth Advisors LLC. Company insiders that have bought Pluristem Therapeutics stock in the last two years include Clover Wolf Capital - Limited, Moria Kwiat, and Yaky Yanay. View insider buying and selling activity for Pluristem Therapeutics. How do I buy shares of Pluristem Therapeutics? Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Pluristem Therapeutics' stock price today? One share of PSTI stock can currently be purchased for approximately $8.74. How big of a company is Pluristem Therapeutics? Pluristem Therapeutics has a market capitalization of $222.81 million and generates $50,000.00 in revenue each year. Pluristem Therapeutics employs 172 workers across the globe. What is Pluristem Therapeutics' official website? The official website for Pluristem Therapeutics is www.pluristem.com. How can I contact Pluristem Therapeutics? Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409. The biotechnology company can be reached via phone at 972-74-710-8600 or via email at [email protected] This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
